Robert W. Baird reaffirmed their buy rating on shares of Danaher (NYSE:DHR) in a research note published on Friday morning.

Several other research firms have also recently commented on DHR. Zacks Investment Research cut shares of Danaher from a buy rating to a hold rating in a research note on Tuesday, December 19th. Credit Suisse Group reaffirmed a hold rating and issued a $99.00 target price on shares of Danaher in a research note on Tuesday, December 19th. Royal Bank of Canada reaffirmed a hold rating and issued a $96.00 target price on shares of Danaher in a research note on Thursday, January 4th. Evercore ISI began coverage on shares of Danaher in a research note on Wednesday, January 3rd. They issued an outperform rating for the company. Finally, Citigroup lifted their target price on shares of Danaher to $107.00 and gave the stock a buy rating in a research note on Friday, December 15th. One analyst has rated the stock with a sell rating, six have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $94.91.

Shares of Danaher (NYSE DHR) traded up $0.80 on Friday, hitting $99.39. 1,894,500 shares of the stock were exchanged, compared to its average volume of 2,517,444. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43. Danaher has a fifty-two week low of $78.97 and a fifty-two week high of $99.66. The stock has a market cap of $69,140.00, a PE ratio of 29.58, a price-to-earnings-growth ratio of 2.15 and a beta of 1.03.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.95 by $0.05. The business had revenue of $4.53 billion during the quarter, compared to analysts’ expectations of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The company’s revenue was up 9.6% on a year-over-year basis. During the same period last year, the company posted $0.87 EPS. equities analysts expect that Danaher will post 3.99 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be issued a $0.14 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.56%. Danaher’s dividend payout ratio (DPR) is presently 16.67%.

In other Danaher news, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of Danaher stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $92.64, for a total value of $11,671,620.96. Following the transaction, the chief executive officer now owns 271,737 shares in the company, valued at approximately $25,173,715.68. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Robert S. Lutz sold 11,189 shares of Danaher stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $91.66, for a total transaction of $1,025,583.74. Following the completion of the transaction, the chief accounting officer now owns 18,314 shares in the company, valued at approximately $1,678,661.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 273,810 shares of company stock worth $25,218,813. 12.20% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in DHR. Point72 Asset Management L.P. lifted its holdings in shares of Danaher by 276.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,626,865 shares of the conglomerate’s stock valued at $225,332,000 after acquiring an additional 1,929,751 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Danaher by 16,410.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock valued at $125,395,000 after acquiring an additional 1,476,901 shares in the last quarter. Findlay Park Partners LLP lifted its holdings in shares of Danaher by 52.9% during the 3rd quarter. Findlay Park Partners LLP now owns 4,117,348 shares of the conglomerate’s stock valued at $353,186,000 after acquiring an additional 1,425,000 shares in the last quarter. Koch Industries Inc. lifted its holdings in shares of Danaher by 29,127.3% during the 2nd quarter. Koch Industries Inc. now owns 1,404,665 shares of the conglomerate’s stock valued at $1,388,000 after acquiring an additional 1,399,859 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Danaher by 86.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,011,947 shares of the conglomerate’s stock valued at $256,136,000 after acquiring an additional 1,393,165 shares in the last quarter. Institutional investors own 76.11% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2018/01/16/danaher-dhr-stock-rating-reaffirmed-by-robert-w-baird.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.